Delivery Order SPE2DB24D1006-SPE2DB25FCFDL
- Not listed
- The Defense Logistics Agency awarded a $10,547.87 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count). This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $7,548.39 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-unit supply) on May 27, 2025, with completion targeted for May 28, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a $17,816.82 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units). This is a non-set-aside competitive award with an ultimate completion date of September 10, 2025, and represents a child delivery order under AmerisourceBergen's larger contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,910.27 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) with a firm fixed price contract type. This award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,251.90 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation medication used in respiratory disease treatment. This firm fixed-price, non-set-aside contract was awarded on August 15, 2025, with an ultimate completion date of August 18, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $29,315.47 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count unit) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,415.62 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count units) on July 14, 2025, with completion expected by July 15, 2025. This firm fixed price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999.999 billion through December 2026. The product is being delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $21,488.46 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and serves as a major...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCFDLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) valued at $19,488.02. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 19, 2025, with performance occurring at the vendor's Conshohocken, Pennsylvania headquarters. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete successfully in open federal procurement processes for pharmaceutical supplies. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and prime vendor for federal medical procurement, AmerisourceBergen supplies critical medications and medical supplies to support military healthcare systems and other government agencies including the Defense Health Agency and U.S. Coast Guard. TRELEGY ELLIPTA is a combination respiratory medication used in the treatment of chronic obstructive pulmonary disease, reflecting the company's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.5k | 9/18/25 |